Royal Bank Of Canada Has Lowered Expectations for Smith & Nephew (LON:SN) Stock Price

Smith & Nephew (LON:SN) had its price target lowered by investment analysts at Royal Bank Of Canada from GBX 1,350 to GBX 1,250 in a report released on Thursday, MarketBeat Ratings reports. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 12.31% from the stock’s current price.

Several other research analysts have also weighed in on SN. Shore Capital Group reiterated a “buy” rating and issued a GBX 1,000 price objective on shares of Smith & Nephew in a research report on Tuesday, July 21st. JPMorgan Chase & Co. reduced their target price on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 1,500 price target on shares of Smith & Nephew in a research note on Wednesday. UBS Group reissued a “neutral” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a research report on Tuesday, May 5th. Finally, Citigroup lowered shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Smith & Nephew currently has an average rating of “Hold” and a consensus target price of GBX 1,172.56.

Smith & Nephew Price Performance

LON:SN opened at GBX 1,113 on Thursday. The company has a fifty day moving average price of GBX 1,135.36 and a 200-day moving average price of GBX 1,192.51. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07. The firm has a market cap of £12.20 billion, a price-to-earnings ratio of 40.07, a price-to-earnings-growth ratio of 0.46 and a beta of 0.69.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.